-
<![CDATA[Dabrafenib Combo Confers PFS Benefit in RAI-Refractory BRAF V600-Mutant DTC]]>
22 Oct 2025 21:46 GMT
In this global, multicenter, randomized, double-blind phase 3 study, 153 adult patients with locally advanced or metastatic DTC were randomized 2:1 to receive either D+T combination therapy (n=101) or placebo (n=52), with a median follow-up time of 17.4 …
-
Keytruda plus Lenvima demonstrates durable 5─year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum─based regimen
20 Oct 2025 04:58 GMT
… Eisai announced long-term follow-up data continued to show durable benefit … trial show sustained survival benefit in patients treated … the durable survival benefit of Keytruda plus … Eisai Inc. “These findings demonstrate the continued overall survival benefit …
-
<![CDATA[Diagnosis and Management of Unresectable HCC Using Clinical Criteria]]>
23 Oct 2025 21:17 GMT
… safe and maybe has some benefit. The problem is Child Pugh … Myers Squibb, Roche/Genentech, Eisai, Merck, Agenus, Exelixis, AstraZeneca… with Bristol Myers Squibb, Bayer, Eisai, Roche, Merck, Exelixis, Pieris Pharmaceuticals …
-
<![CDATA[Trial Data Show Savolitinib Does Not Improve Outcomes for Patients with RCC]]>
23 Oct 2025 21:18 GMT
… we don’t see any benefit in terms of PFS and … Pharma, Bristol-Myers Squibb, Daiichi, Eisai, Ipsen, Janssen, Merck, MSD, Novartis …
-
Prevalence of Multiple Chronic Conditions in Older Adults with Undiagnosed Mild Cognitive Impairment and Alzheimer’s Disease and Related Dementias in Primary Care
23 Oct 2025 16:08 GMT
… more medications –many with conflicting benefit-harm profiles.25–32 This … this year with no financial benefits gained by Dr. Boustani. … for Eli Lilly and Co; Eisai, Inc; Merck & Co … Biogen, Bristol Myers Squibb (BMS), Eisai, Eli Lilly, GE Healthcare, Lobe …
-
<![CDATA[Treating Metastatic DTC After Radioactive Iodine Progression]]>
22 Oct 2025 21:45 GMT
… patient like that might still benefit from RAI, as some lesions … or advisory role with Merck, Eisai, Lilly, Bayer, Exelixis, Coherus Biosciences …
-
<![CDATA[Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC]]>
22 Oct 2025 19:16 GMT
… arms until loss of clinical benefit, unacceptable toxicity, or patient withdrawal … , Boston Scientific, AstraZeneca, Adaptimmune, BMS, Eisai, MSD, Sirtex, Lilly, Roche, and …
-
Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight
21 Oct 2025 22:44 GMT
… tolerability, potentially providing more durable benefits for patients who do not … the same endpoint despite early benefits.
In March 2025, Japan … , Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant …
-
Merck grows more ambitious about 'workhorse' TROP2 ADC as partner Kelun posts phase 3 wins
21 Oct 2025 00:23 GMT
… and chemo, Merck’s Eisai-partnered Lenvima—used in tandem … of uncertainty about Merck and Eisai’s plans and whether … months in the chemo group.
Benefits were observed across subgroups analyzed … levels.
Sac-TMT’s PFS benefit was also statistically significant, …
-
Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight
20 Oct 2025 23:43 GMT
… reducing local recurrence, while the benefits of perioperative radiotherapy remain uncertain … , Johnson & Johnson Innovative Medicine, Eisai, and others
Key Liposarcoma Therapies …
11.3
HALAVEN (eribulin mesylate): Eisai
List to be continued in …
About
© 1995-2025